CRDF (Cardiff Oncology) YoY EBITDA Growth: 36.49% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRDF Cardiff Oncology Inc CRDF
26 GF Score
Price $1.21
! 5 Warning Signs
View Full Analysis

What is Cardiff Oncology YoY EBITDA Growth?

Cardiff Oncology CRDF -0.41% 26 YoY EBITDA Growth is 36.49% as of Jun. 2026. GuruFocus rates CRDF with a GF Score™ of 26/100. The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cardiff Oncology's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 36.49%.

Cardiff Oncology's EBITDA per Share for the three months ended in Jun. 2026 was $-0.14.

Cardiff Oncology YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology YoY EBITDA Growth Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.29 -25.00 -10.77 0.69 28.17

Cardiff Oncology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.71 33.33 50.44 13.15 36.49
CRDF
26GF Score
Cardiff Oncology Inc CRDF
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cardiff Oncology's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.719--1.001)/ | -1.001 |
=28.17 %

Cardiff Oncology's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.141--0.222)/ | -0.222 |
=36.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 36.49% mean?
Cardiff Oncology (CRDF) has a YoY EBITDA Growth of 36.49% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cardiff Oncology and its competitors.
Is Cardiff Oncology's YoY EBITDA Growth too high?
Cardiff Oncology's current YoY EBITDA Growth is 36.49%. Overall, Cardiff Oncology has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's YoY EBITDA Growth compare to ANVS and ELTX?
Cardiff Oncology's YoY EBITDA Growth of 36.49% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cardiff Oncology and its competitors. Cardiff Oncology's current YoY EBITDA Growth is 36.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (CRDF) has a current YoY EBITDA Growth of 36.49%. The current YoY EBITDA Growth is 36.49%. Cardiff Oncology's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current YoY EBITDA Growth is 36.49% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiff Oncology Business Description

Other Exchanges XE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
26GF Score

Get the complete analysis for CRDF

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.21
Price